Laboratory Billing Services
A reference laboratory processing 8,000 tests per month watched 24% of its claims deny on medical necessity until someone reconciled the orders against the Medicare NCD/LCD diagnosis-to-test pairings — a single fix that recovered $94,000 a year and eliminated panel-versus-component overbilling that had been silently inviting clawbacks. Laboratory billing operates inside CPT 80000–89999, the diagnostic immunology, microbiology, chemistry, hematology, and molecular pathology series, plus the Proprietary Laboratory Analyses (PLA) codes the AMA assigns to specific manufacturer-branded tests. The panel codes — 80048 basic metabolic panel, 80053 comprehensive metabolic panel, 80061 lipid panel, 80050 general health panel — pay one bundled rate but require that every listed component be performed; bill the panel without one component and the entire claim is fraudulent overbilling, bill components individually when the panel was performed and you forfeit the bundling efficiency. CLIA certification levels (Waiver, PPM, Moderate Complexity, High Complexity) cap which tests a given lab can perform and bill. The 14-day rule (specimens collected during a hospital stay must be billed by the hospital, not the reference lab) and the Date of Service rule (DOS is the date the specimen was collected, not the date it was analyzed) both create timing-driven denials when ignored. Add PAMA-driven Medicare clinical lab fee schedule cuts phasing in through 2026 and the venipuncture vs. specimen handling fee distinction (CPT 36415 versus 99000 versus 99001), and lab billing becomes a high-volume, low-margin operation where small per-test errors multiply into six-figure annual losses.
Who This Page Is For
Common Billing Friction in Laboratory
Panel versus component billing and the all-or-nothing rule
Each AMA-defined laboratory panel — 80048 BMP, 80053 CMP, 80061 lipid panel, 80050 general health, 80055 obstetric — requires that all listed component tests be performed and reported. Billing the panel when one component was missing exposes the lab to overbilling clawbacks; billing the components individually when the panel was performed loses the bundling-efficient reimbursement and triggers automated denials when payer logic detects the unbundling pattern. The order set design upstream of the lab determines the correct billing pattern: a 'CMP' order produces a panel claim, a 'sodium and potassium only' order produces individual component claims. Practices that rebuild order sets to match billing intent recover materially without changing testing volume.
NCD/LCD medical necessity diagnosis-to-test pairing
Medicare publishes National Coverage Determinations and Local Coverage Determinations for high-volume tests including TSH (84443), vitamin D (82306), HbA1c (83036), and PSA (84153) that specify which ICD-10 diagnoses establish medical necessity. Claims without a qualifying diagnosis return CO-50 (medically necessary services not covered) and cannot be billed to the patient unless an Advance Beneficiary Notice was issued before the test. Diagnosis-validation logic at order entry — verifying the ordering diagnosis matches the LCD covered list before specimen collection — is the only economical defense against medical-necessity denials at high test volume.
CLIA certification scope and the high-complexity test boundary
Labs operate under one of four CLIA categories: Certificate of Waiver (rapid strep, urine dipstick, glucose, pregnancy), Provider-Performed Microscopy, Moderate Complexity, or High Complexity. Each test on the FDA's CLIA categorization list is assigned to one category, and a lab cannot bill for tests above its certified scope. A waiver-only lab billing CPT 87880 (rapid strep) is fine; the same lab billing 87651 (strep PCR) triggers CMS sanctions. Practices expanding test menus must check both the new test's CLIA category and verify their certificate covers it before going live.
Date of Service rule, 14-day rule, and hospital-collected specimen routing
CMS Date of Service rules set DOS as the date the specimen was collected, not the date the lab ran the analysis — important when a specimen is shipped to a reference lab that runs the test days later. The 14-day rule routes hospital-inpatient-collected specimens to the hospital's bill: if a specimen is collected during an inpatient stay or within 14 days of an outpatient procedure, the reference lab cannot bill Medicare directly; the hospital bills the test under the inpatient DRG or outpatient procedure bundle. Mishandled, the reference lab bills directly, the claim pays, then CMS recoups when the hospital claim is reconciled.
PAMA fee schedule cuts, ABN execution, and molecular diagnostic PLA codes
The Protecting Access to Medicare Act phased in private-payer-derived rates for the Medicare Clinical Laboratory Fee Schedule, cutting reimbursement on high-volume tests through annual reductions. UnitedHealthcare and Aetna often hold their own commercial lab fee schedules below PAMA rates, so the same 80053 CMP can pay $14 to Medicare and $9 to a commercial plan on the same day. ABN execution must occur before specimen collection on tests that may not be covered, with patient signature, and using the current OMB-approved form; missing or post-dated ABNs prevent patient billing on subsequent denials. Molecular diagnostics use PLA codes (e.g., 0001U–0xxxU range) and standard tier 1 (81161–81479 specific gene tests) and tier 2 (81400–81408 by gene type) molecular pathology codes — payer formularies and coverage criteria differ significantly across these series.
Laboratory-Specific Payer Issues We Watch For
Medicare
Issue: National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) specify which diagnosis codes support medical necessity for each lab test — claims without qualifying diagnoses are automatically denied
Our approach: We maintain a diagnosis-to-test validation matrix based on current NCDs and LCDs and validate every claim against medical necessity requirements before submission
UnitedHealthcare
Issue: Applies its own lab fee schedule that is often lower than PAMA rates and denies claims billed at Medicare rates for UHC patients
Our approach: We maintain UHC-specific lab fee schedules and verify contracted rates against billed amounts to prevent overcharge denials and underpayments
BCBS
Issue: Requires that lab tests be ordered by a physician within the same BCBS network and denies claims when the ordering provider is out of network even if the lab is in network
Our approach: We verify ordering provider network status for each BCBS claim before submission and flag out-of-network ordering providers for patient notification
Aetna
Issue: Bundles certain genetic and molecular tests with conventional lab panels, denying separate payment for advanced tests ordered alongside routine panels
Our approach: We separate genetic and molecular test submissions from routine panel claims and document distinct clinical indications for each test category
What We Handle
Panel and component coding (80048, 80053, 80061, 80050) with all-component verification
Order-set-to-bill reconciliation that matches panel billing only when all components were performed and component billing when the order specified individual analytes. Unbundling-pattern detection prevents automated denials at the clearinghouse.
ABN execution workflow and patient-billable conversion on Medicare denials
OMB-approved ABN form execution before specimen collection on potentially non-covered tests, with patient signature and tracking. GA modifier on the claim to indicate ABN on file; conversion to patient-billable status when Medicare denies for medical necessity.
Molecular diagnostics billing (tier 1 81161–81479, tier 2 81400–81408, PLA 0xxxU)
Tier 1 specific-gene, tier 2 gene-type-grouped, and PLA proprietary test billing with payer formulary verification and prior auth submission. G0306 Medicare professional component billing where applicable.
Venipuncture (36415), capillary draw (36416), and specimen handling fees (99000, 99001)
Routine venipuncture, capillary blood specimen, and specimen-handling/transfer billing. In-house collection plus reference-lab send-out coordination with proper handling-fee capture often missed in practice settings.
Reference lab send-out coordination and 14-day rule routing
Hospital-collected specimen routing per the 14-day rule, Date of Service rule application (collection date, not analysis date), and reference-lab-versus-ordering-provider billing attribution to prevent duplicate claims and CMS recoupment.
NCD/LCD diagnosis-validation matrix at order entry
ICD-10 diagnosis to CPT lab test validation against current Medicare NCDs and contractor-specific LCDs (Novitas, NGS, Palmetto, WPS, FCSO). Order-time validation prevents medical-necessity denials before specimen collection.
Key Laboratory CPT Codes
| CPT Code | Description | Avg. Reimbursement |
|---|---|---|
| 80053 | Comprehensive metabolic panel | $14 |
| 85025 | Complete blood count with differential | $11 |
| 81001 | Urinalysis with microscopy | $4 |
| 80061 | Lipid panel | $18 |
| 84443 | Thyroid stimulating hormone (TSH) | $23 |
| 82947 | Glucose quantitative, blood | $5 |
| 36415 | Routine venipuncture for specimen collection | $3 |
| 87086 | Urine culture, quantitative | $12 |
| 88305 | Surgical pathology, gross and microscopic | $75 |
Real Results
The Challenge
A reference laboratory processing 8,000 tests monthly was losing revenue on panel tuning, had a 24% denial rate due to missing medical necessity diagnoses, and was not billing for specimen handling fees
Our Approach
We analyzed test ordering patterns for panel tuning opportunities, implemented diagnosis code validation against NCD/LCD requirements before claim submission, and added specimen collection and handling fee capture
Key Outcomes
- check_circle Panel vs individual test tuning saved $94K in payer clawbacks annually
- check_circle Medical necessity denial rate dropped from 24% to 5%
- check_circle Specimen handling fee capture added $3,800 per month
- check_circle Overall collections increased by 18%
“We were overbilling panels when individual tests were cheaper and underbilling by missing handling fees. MedPrecision tuned both directions.”
Why General Billing Teams Miss Laboratory Issues
General billing staff handle dozens of specialties and rarely develop the depth needed for laboratory coding nuances. Here is what gets missed.
Modifier and bundling errors
Specialty-specific modifier rules and CCI edits are frequently overlooked by teams that do not work exclusively in laboratory.
Under-coding high-complexity visits
Laboratory encounters often qualify for higher-level E/M codes, but generalist billers default to mid-level codes to avoid audit risk.
Missed payer-specific rules
Each payer has unique coverage and documentation requirements for laboratory procedures that general teams rarely memorize.
Slow denial turnaround
Without specialty knowledge, appeal letters lack the clinical specificity needed to overturn laboratory denials quickly.
“Laboratory billing is a volume game where small per-test errors multiply into six-figure annual losses. The difference between a profitable lab and a struggling one is often just diagnosis validation and panel tuning.”
MedPrecision Billing Team
Laboratory Billing Compliance Director
Transition Plan
Switching billing partners should not disrupt patient care or cash flow. Our transition plan is designed for zero downtime.
Discovery and Specialty Audit
We review your current laboratory billing workflows, denial patterns, and payer mix to build a tailored onboarding plan.
System Integration
We connect to your EHR and practice management system, configure specialty-specific code sets, and validate charge capture workflows.
Parallel Billing Period
We run billing in parallel with your current process for 2-4 weeks to verify accuracy before taking over completely.
Full Transition and Reporting
Once validated, we assume full billing responsibility with monthly reporting dashboards and a dedicated account manager.
Laboratory Billing Terms
- PAMA (Protecting Access to Medicare Act)
- Legislation that reformed Medicare lab fee schedules based on private payer rates reported by labs. PAMA rates are phased in over multiple years and have significantly reduced Medicare reimbursement for many high-volume lab tests.
- Panel Optimization
- The billing decision between coding individual tests versus a bundled panel code. Sometimes billing individual tests is more cost-effective than a panel (or vice versa). Tuning ensures the highest compliant reimbursement for each order.
- NCD/LCD (National/Local Coverage Determination)
- Medicare policies that specify which diagnoses and clinical scenarios support medical necessity for specific lab tests. Claims without a qualifying diagnosis code linked to the ordered test are denied as not medically necessary.
- ABN (Advance Beneficiary Notice)
- A form issued to Medicare patients before performing lab tests that may not be covered, notifying them of potential financial responsibility. Required to bill the patient if Medicare denies the claim for medical necessity.
- Specimen Handling Fee
- A separately billable fee (99000-99001) for the collection, processing, and transportation of laboratory specimens. Often missed by practices that perform in-house collection but send specimens to reference labs.
- CLIA Waived Tests
- Laboratory tests approved by CMS for performance in settings with a CLIA Certificate of Waiver. These point-of-care tests (rapid strep, urine dipstick, glucose) have lower regulatory requirements but still require proper coding and billing.
Last updated: 2026-03-13
Common Questions
Common questions about laboratory billing services.
Request a Specialty Billing Review
See how specialty-specific billing support can improve reimbursement visibility for laboratory billing services.
Request Review arrow_forwardWhen should we bill a panel code versus individual test codes?
Bill the panel code when all component tests included in the panel are ordered and performed. If only some components are needed, bill individual test codes. We analyze your ordering patterns to identify opportunities for panel billing accuracy and create order set recommendations.
How do you handle billing for reference laboratory send-out tests?
For send-out tests, we ensure proper ordering provider information is captured, bill under your laboratory's NPI when appropriate, and coordinate with the reference lab to prevent duplicate billing. We manage the fee schedule differential to ensure profitability on send-out testing.
What is required for molecular diagnostic test billing?
Molecular testing requires specific PLA or CPT codes, prior authorization for many payers, ordering provider documentation of medical necessity, and often a specimen type verification. We verify coverage before testing, submit authorizations, and use payer-specific code crosswalks for molecular diagnostics.
Related Specialties
Related Resources
Available In
Request a Specialty Billing Review
See if your lab panel unbundling, CLIA waiver billing, and reference lab coding are increasing collections.